{
    "id": "item-1761036952938-p8ug8mj96",
    "type": "ehr-data",
    "title": "Imaging Report - Sarah Miller radiology data",
    "content": "**Imaging Study:** Imaging - Sarah Miller radiology data\n\n**Patient:** Sarah Miller (MRN: MC-001001)\n**Date:** October 21, 2025\n**Study Type:** Imaging\n\n**Clinical Indication:**\nEvaluation for suspected drug-induced liver injury (DILI) secondary to methotrexate toxicity.\n\n**Technique:**\nStandard imaging imaging protocol performed.\n\n**Findings:**\n• Liver: Hepatomegaly with increased echogenicity consistent with steatosis\n• Liver measures 18 cm in craniocaudal dimension (upper limit normal 16 cm)\n• Parenchyma shows diffusely increased echogenicity\n• No focal lesions, masses, or cysts identified\n• Portal vein patent with normal hepatopetal flow\n• Main portal vein diameter: 11 mm (normal)\n• Hepatic veins patent\n• Gallbladder: Normal wall thickness, no stones or sludge\n• Common bile duct: Normal caliber at 4 mm\n• Spleen: Normal size (10 cm) and echotexture\n• Kidneys: Bilateral normal size and echotexture, no hydronephrosis\n• No ascites identified\n\n**Impression:**\n1. Hepatomegaly with diffuse increased echogenicity suggesting hepatic steatosis\n2. Findings compatible with drug-induced liver injury\n3. No focal hepatic lesions identified\n4. No biliary dilatation or gallstones\n\n**Recommendations:**\n• Clinical correlation with liver function tests recommended\n• Follow-up imaging in 6-8 weeks to assess response to treatment modifications\n• Consider hepatology consultation for further management\n\n**Radiologist:** Dr. Johnson, MD\n**Report Date:** October 21, 2025\n",
    "dataType": "radiology-report",
    "source": "Radiology Department",
    "x": 4260,
    "y": -4540,
    "width": 400,
    "height": 300,
    "timestamp": "2025-10-21T08:55:52.939Z"
}